Deoxymab 3E10

Deoxymab 3E10 is a first-in-class DNA damage-repair antibody platform originally identified as a lupus-derived autoantibody from a mouse model of systemic lupus erythematosus. Developed by Patrys Limited, this technology utilizes a unique mechanism where the antibody penetrates cell nuclei via the Equilibrative Nucleoside Transporter 2 (ENT2) and binds directly to DNA. Once inside the nucleus, it inhibits DNA repair pathways, leading to synthetic lethality in cancer cells with existing DNA repair deficiencies, such as those lacking BRCA or PTEN. The platform includes humanized variants like PAT-DX1 (a di-scFv dimer fragment) and PAT-DX3 (a full-sized IgG antibody). These agents are notable for their ability to cross the blood-brain barrier, making them promising candidates for treating primary and metastatic brain tumors. Beyond oncology, the platform has shown potential in treating inflammatory conditions like ANCA-associated vasculitis by reducing neutrophil extracellular traps (NETs).

Other names

3E10 antibodyDeoxymab